Neuronetics, Inc. Raises $15 Million in Series G Equity Financing, Led by Ascension Ventures Capital will help expand clinical adoption of NeuroStar® Advanced Therapy, the company’s market-leading transcranial magnetic stimulation (TMS) treatment MALVERN,...
AbbVie and Principia Annouce Collaboration on Oral Immunoproteasome Inhibitors NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., June 13, 2017 – AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage...
Deciphera Pharmaceuticals Announces $52 Million Series C Financing to Advance Novel Clinical-stage Oncology Pipeline Waltham, MA | June 1, 2017 Deciphera Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug...
Harpoon Therapeutics Announces Completion Of $45M Series B Financing MPM Capital, Arix Bioscience, New Leaf Venture Partners and Taiho Ventures Participate in Immuno-Oncology Financing South San Francisco, CA—May 25, 2017-Harpoon Therapeutics, a biotechnology company...
Bioverativ to Acquire Clinical-Stage Rare Disease Biotechnology Company, True North Therapeutics – Strengthens pipeline with lead candidate TNT009 in cold agglutinin disease, a rare and chronic autoimmune hemolytic anemia with no approved therapies –...
Versartis Presents 3-Year Somavaratan Safety and Efficacy Data and Pediatric Program Baseline Demographics at the 19th European Congress of Endocrinology MENLO PARK, Calif., May 22, 2017 (GLOBE NEWSWIRE) — Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused...
Recent Comments